Elizabeth McFarland, MD
Professor, Pediatrics-Infectious Diseases

Section Chief, Pediatric Infectious Diseases
Medical Director, Children's Hospital Colorado HIV Program
Professor of Pediatrics
Clinic (720) 777-6981
Print Profile
Email Profile
Featured Provider Photo

Gender: Female
Languages: English
Department, Section/Division: Pediatrics-Infectious Diseases
Medicine-Infectious Disease

Practice Locations

Children's Hospital Colorado Anschutz Medical Campus
13123 East 16th Ave
Aurora, CO 80045
720-777-1234
More providers at this location

Hospital Affiliation
  • Children's Hospital Colorado

Specialty Information

Specialties
  • Pediatrics - Pediatric Infectious Diseases, Board Certification (1992,2008)
  • Pediatrics, Board Certification (1990,2014)
Conditions & Treatments
  • Immune System
  • AIDS
  • AIDS / HIV Disease
  • AIDS Immunization
  • Infections
  • Bacterial Infections
  • Fungal Infections
  • Influenza
  • Pneumonia
  • Viral Infections
  • Kawasaki Disease
  • Symptoms and Manifestations
  • Fever
Clinical Interest for Patients
I am interested in pediatric infectious diseases, particularly pediatric and perinatal HIV Infection.

Education & Training

Medical Schools:
  • MD, Duke University School of Medicine (1985)

Undergraduate Schools:
  • BS, Northwestern University (IL) (1981)

Internships:
  • University of Colorado (University Hospital) Program (1986)

Residency Program:
  • University of Colorado (University Hospital) Program, Pediatrics (1988)

Fellowships:
  • University of Colorado (University Hospital) Program, Pediatric Infectious Diseases (1992)

Professional Memberships

  • Pediatric Infectious Disease Society, Member

Research & Grants

Research interests for Patients:
Dr. McFarland’s primary areas of research interest are HIV passive and active immunization and immune-based HIV therapy, the role of HIV-specific cell-mediated immunity in HIV pathogenesis and response to therapy and RSV vaccine clinical trials. She is leading clinical research protocols focused on HIV-1 specific broadly neutralizing monoclonal antibody (bNAb) for infants exposed to HIV-1 and for infant early antiretroviral treatment. She serves as Vice Chair of the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) HIV Cure Committee, as member of the Pediatric Advisory Committee to the HIV Vaccine Trials Network (HVTN), as a co-investigator for the Pediatrics Adolescent Virus Eradication (PAVE) Martin Delaney Collaboratory, site principal investigator for the multicenter Pediatric AIDS/HIV Cohort Study (PHACS), and member of the PHACS Nutrition, Metabolic, Growth Working Group. She has served on the AIDS Research Advisory Council, Division of AIDS (DIADS) at the National Institutes of Health (NIH). Dr. McFarland has had continuous NIH and HRSA funding since 1995.

Information for Referring Providers

Clinical Interests for Referring Providers
I am interested in pediatric infectious diseases, particularly pediatric and perinatal HIV Infection.

Research Interest for Referring Providers
Dr. McFarland’s primary areas of research interest are HIV passive and active immunization and immune-based HIV therapy, the role of HIV-specific cell-mediated immunity in HIV pathogenesis and response to therapy and RSV vaccine clinical trials. She is leading clinical research protocols focused on HIV-1 specific broadly neutralizing monoclonal antibody (bNAb) for infants exposed to HIV-1 and for infant early antiretroviral treatment. She serves as Vice Chair of the International Maternal Pediatric Adolescent AIDS Clinical Trials (IMPAACT) HIV Cure Committee, as member of the Pediatric Advisory Committee to the HIV Vaccine Trials Network (HVTN), as a co-investigator for the Pediatrics Adolescent Virus Eradication (PAVE) Martin Delaney Collaboratory, site principal investigator for the multicenter Pediatric AIDS/HIV Cohort Study (PHACS), and member of the PHACS Nutrition, Metabolic, Growth Working Group. She has served on the AIDS Research Advisory Council, Division of AIDS (DIADS) at the National Institutes of Health (NIH). Dr. McFarland has had continuous NIH and HRSA funding since 1995.
Clinic Phone: (720) 777-6981
Fax Phone: (720) 777-7294